A Comprehensive Monograph on Adefovir Dipivoxil: Pharmacology, Clinical Efficacy, and Therapeutic Context

Executive Summary

Adefovir dipivoxil is an orally administered diester prodrug of adefovir, classified as an acyclic nucleotide analog reverse-transcriptase inhibitor (ntRTI). Its primary therapeutic indication is the treatment of chronic hepatitis B (CHB) infection in adults and adolescents aged 12 years and older. The drug functions by undergoing intracellular conversion to its active diphosphate metabolite, which then competitively inhibits the hepatitis B virus (HBV) DNA polymerase and terminates viral DNA chain synthesis, thereby suppressing viral replication.

The development history of adefovir dipivoxil is a notable case study in pharmaceutical repurposing. Initially investigated by Gilead Sciences as a treatment for HIV infection under the brand name Preveon, it failed to gain regulatory approval due to significant dose-limiting nephrotoxicity at the high doses required for anti-HIV efficacy. However, the compound was successfully repurposed for CHB, for which a much lower and better-tolerated dose of 10 mg daily proved effective. It received FDA approval in 2002 under the brand name Hepsera®, representing a significant therapeutic advance at the time, particularly for patients with lamivudine-resistant HBV, as it possessed a higher genetic barrier to resistance than first-generation nucleoside analogs.

Despite its initial success, the therapeutic role of adefovir dipivoxil has been largely superseded by newer, more potent agents such as tenofovir disoproxil fumarate (TDF) and entecavir (ETV). Clinical evidence from multiple head-to-head trials and meta-analyses has conclusively demonstrated the superiority of these agents in achieving virologic suppression.

The safety profile of adefovir dipivoxil is dominated by the risk of nephrotoxicity, a concern that necessitates careful patient selection, routine monitoring of renal function, and mandatory dose adjustments in patients with renal impairment. This risk is underscored by an FDA boxed warning, alongside other serious warnings for post-treatment exacerbations of hepatitis, the potential for developing HIV resistance in co-infected patients, and the class-wide risk of lactic acidosis and severe hepatomegaly. The drug's pharmacokinetic profile is characterized by a lack of CYP450 enzyme interactions, simplifying co-medication regimens, but its near-complete reliance on renal elimination is the basis for its primary toxicity.

Reflecting its displacement by more effective therapies, the marketing authorization for Hepsera® was withdrawn from the European Union in 2022 for commercial reasons. While it may retain a niche role in certain resource-limited settings as a generic option, adefovir dipivoxil is now considered a legacy drug in most contemporary treatment guidelines—a historically important stepping stone in the evolution of CHB therapy but one that has been surpassed by more advanced treatments.

Drug Identification and Physicochemical Properties

Adefovir dipivoxil is a small molecule drug that functions as a prodrug of adefovir. Its precise chemical and physical identification is fundamental to its use in clinical and research settings.

Nomenclature and Identifiers

The compound is known by several names and is cataloged across numerous international scientific databases. The proliferation of trade names beyond its primary brand reflects a robust post-patent generic market, particularly in regions where CHB is highly prevalent, such as Asia, suggesting its continued use as a lower-cost alternative in specific global health contexts.[1]

• Generic Name: Adefovir dipivoxil.[2]
• English Name: Adefovir dipivoxil [User Query].
• Brand Names: The most widely recognized brand name is Hepsera®.[3] It was also developed under the name Preveon® during its initial investigation as an HIV therapy, though this was never commercially approved.[3] Numerous other generic trade names exist, including A Di Xian, Adesera, Adfovir, and Dinghe.[1]
• Code Names: Development codes for the compound include GS-0840 and bis-POM PMEA.[3]
• Database Identifiers: The drug is uniquely identified by its DrugBank ID (DB00718) and CAS (Chemical Abstracts Service) Number (142340-99-6). It is important to distinguish this from the CAS number for its active moiety, adefovir, which is 106941-25-7.[3]

Table 1 provides a consolidated list of key identifiers and physicochemical properties for adefovir dipivoxil.

Table 1: Key Drug Identifiers and Physicochemical Properties

Property	Value	Source(s)
Generic Name	Adefovir dipivoxil	2
Brand Name	Hepsera®, Preveon® (unapproved)	3
DrugBank ID	DB00718	2
CAS Number	142340-99-6	9
PubChem CID	60871	10
UNII	U6Q8Z01514	3
Molecular Formula	C20​H32​N5​O8​P	2
Molecular Weight	501.47 g/mol	2
IUPAC Name	[2-(6-aminopurin-9-yl)ethoxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate	10
Appearance	White to off-white crystalline powder	4
Solubility	Aqueous: 19 mg/mL (pH 2.0), 0.4 mg/mL (pH 7.2). Soluble in DMSO, DMF, ethanol (e.g., 30 mg/mL in DMSO).	4
Stability	Stable for ≥ 4 years under proper storage	6

Chemical Structure and Characteristics

Adefovir dipivoxil is chemically classified as an organic phosphonate, a member of the 6-aminopurines, and a carbonate ester.[10] It is the dipivoxil ester of adefovir, meaning it contains two pivaloyloxymethyl (POM) groups attached to the phosphonate moiety.[3] These lipophilic groups are designed to mask the negatively charged phosphonate group of the parent drug, adefovir, thereby enhancing its passive diffusion across the intestinal membrane and improving its oral bioavailability.[3]

The pH-dependent solubility of adefovir dipivoxil is a critical property influencing its biopharmaceutical performance.[4] Its significantly higher solubility in acidic conditions (19 mg/mL at pH 2.0) compared to neutral conditions (0.4 mg/mL at pH 7.2) facilitates its dissolution in the highly acidic environment of the stomach following oral administration. This rapid dissolution is a crucial first step for ensuring adequate absorption in the gastrointestinal tract, linking its fundamental chemical properties directly to its pharmacokinetic behavior.

Detailed crystallographic data for adefovir dipivoxil have been published, defining its solid-state structure with a Hermann-Mauguin space group symbol of C1c1 and specific unit cell dimensions (a = 13.12870 Å, b = 24.6784 Å, c = 8.34752 Å) and angles (β = 100.6575 °).[10]

Pharmacology

The pharmacological activity of adefovir dipivoxil is directed against the hepatitis B virus. Its classification and mechanism of action define its role as an antiviral agent.

Drug Classification

Adefovir dipivoxil is an antiviral medication belonging to the class of acyclic nucleotide analog reverse-transcriptase inhibitors (ntRTIs).[3] It is specifically an analog of adenosine monophosphate.[2]

Mechanism of Action

The antiviral effect of adefovir dipivoxil is achieved through a well-defined, multi-step process that begins with its conversion from an inactive prodrug to an active antiviral agent within the host cell.[11]

1. Prodrug Hydrolysis: Adefovir dipivoxil itself is pharmacologically inactive. After oral administration and absorption, the two pivaloyloxymethyl (pivoxil) ester groups are rapidly cleaved by cellular esterases, which are abundant in the intestines and liver. This hydrolysis reaction releases the active parent drug, adefovir.[2]
2. Intracellular Activation: Once inside the cell, adefovir, which is a nucleotide analog (specifically, an analog of adenosine monophosphate), undergoes two successive phosphorylation steps catalyzed by cellular kinases. This converts it into its pharmacologically active metabolite, adefovir diphosphate.[2]
3. Viral Enzyme Inhibition: Adefovir diphosphate is the ultimate effector molecule. It targets the HBV DNA polymerase, an enzyme that also possesses reverse transcriptase activity and is essential for the replication of the viral genome.[3]
4. Dual Inhibitory Effect: The inhibition of the HBV DNA polymerase occurs through two synergistic mechanisms:

• Competitive Inhibition: Adefovir diphosphate structurally mimics the natural substrate, deoxyadenosine triphosphate (dATP). It competes with dATP for binding to the active site of the viral polymerase, thereby preventing the natural nucleotide from being utilized for DNA synthesis.[2]
• Obligatory Chain Termination: Adefovir diphosphate can be incorporated into the nascent viral DNA strand in place of dATP. However, because adefovir is an acyclic analog, it lacks the crucial 3'-hydroxyl group required to form the next phosphodiester bond. Its incorporation thus results in the immediate and irreversible termination of DNA chain elongation, effectively aborting the viral replication process.[2]

This dual mechanism of competitive inhibition and chain termination provides a potent and specific blockade of HBV replication, leading to a reduction in viral load in treated patients.

Pharmacodynamics

The efficacy and safety of adefovir are determined by the relative affinity of its active metabolite for the viral target enzyme versus host cellular enzymes.

• Potency against HBV: Adefovir diphosphate is a highly potent inhibitor of HBV DNA polymerase, with a reported inhibition constant (Ki​) of 0.1 µM.[2] A lower Ki​ value indicates a higher binding affinity and more potent inhibition.
• Selectivity and Host Cell Safety: The therapeutic utility of an antiviral drug depends on its ability to selectively target the virus without causing excessive harm to the host. Adefovir diphosphate demonstrates this selectivity by being a significantly weaker inhibitor of human DNA polymerases. The Ki​ values for human DNA polymerase α and DNA polymerase γ are 1.18 µM and 0.97 µM, respectively.[2]

The selectivity ratio—the ratio of the Ki​ for a human polymerase to the Ki​ for the viral polymerase—provides a quantitative measure of this safety margin. For mitochondrial DNA polymerase γ, the selectivity ratio is approximately 10-fold (0.97μM/0.1μM≈10). This ratio explains how the drug can achieve therapeutic antiviral concentrations with an acceptable level of host toxicity. However, this selectivity is not absolute. The off-target inhibition of human mitochondrial DNA polymerase γ, even if weak, is the accepted molecular mechanism underlying the potential for long-term mitochondrial toxicity, which can manifest clinically as the rare but serious adverse events of myopathy, severe hepatomegaly with steatosis, and lactic acidosis—all of which are noted in the drug's boxed warnings.[14]

Furthermore, the drug's design as a nucleotide analog, rather than a nucleoside analog like lamivudine, provides a key pharmacological distinction. Nucleoside analogs require three phosphorylation steps for activation, with the first step often being rate-limiting and a potential site for resistance development. As an analog of a monophosphate, adefovir bypasses this first step, requiring only two phosphorylations to become active. This streamlined activation pathway may contribute to its distinct resistance profile compared to earlier nucleoside-based therapies.

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of adefovir dipivoxil describes its journey through the body, from administration to elimination. These properties are crucial for establishing appropriate dosing regimens and understanding the drug's safety and interaction potential. The ADME profile is a "double-edged sword," offering the benefit of minimal metabolic drug interactions while simultaneously creating a significant risk of toxicity in patients with impaired renal function.

Absorption

• Bioavailability: Following oral administration of a 10 mg Hepsera® tablet, the prodrug is rapidly converted to adefovir. The absolute oral bioavailability of adefovir is approximately 59%.[2]
• Plasma Concentrations: A single 10 mg oral dose in patients with CHB results in a mean peak plasma concentration (Cmax​) of adefovir of 18.4 ± 6.26 ng/mL. This peak is reached at a median time (Tmax​) ranging from 0.58 to 4.0 hours after dosing.[2]
• Food Effect: The administration of adefovir dipivoxil with food does not significantly affect the systemic exposure (AUC) to adefovir, allowing it to be taken without regard to meals.[2]
• Drug Interactions at Absorption: A population pharmacokinetic (popPK) analysis suggested that co-administration with a cocktail of other drugs could increase the apparent bioavailability of adefovir to 73.6%.[17] This finding implies that the interaction likely occurs at the level of absorption or first-pass metabolism in the gut, possibly through inhibition of intestinal esterases or efflux transporters, rather than at the level of renal elimination.

Distribution

• Protein Binding: Adefovir exhibits very low binding to human plasma proteins, at less than 4%.[3] This low level of binding means that its distribution is not significantly affected by changes in plasma protein concentrations, and it is less likely to be involved in protein-binding displacement interactions.
• Volume of Distribution: The steady-state volume of distribution is reported to be between 0.35 and 0.39 L/kg, indicating that the drug distributes into extravascular tissues, including its site of action in the liver.[14]

Metabolism

• Prodrug Conversion: Adefovir dipivoxil is extensively metabolized, but this metabolism is limited to the intended hydrolysis of the pivoxil ester groups to release the active drug, adefovir.[2]
• Cytochrome P450 (CYP450) System: A key feature of adefovir's pharmacokinetic profile is that it is not a substrate, inhibitor, or inducer of the CYP450 enzyme system.[2] This is a significant clinical advantage, as it minimizes the potential for drug-drug interactions with the many medications that are metabolized by these enzymes.

Excretion

• Primary Route: Adefovir is eliminated primarily by the kidneys through a combination of glomerular filtration and active tubular secretion.[3]
• Urinary Recovery: At steady state, approximately 45% of an administered dose is recovered as unchanged adefovir in the urine over a 24-hour period.[2]
• Elimination Half-Life: The terminal elimination half-life of adefovir is approximately 7.5 hours in patients with normal renal function, which supports a once-daily dosing interval.[3]
• Renal Clearance: Renal clearance is high in individuals with unimpaired renal function but is drastically reduced in patients with renal insufficiency. For example, clearance can drop from approximately 469 mL/min in healthy individuals to 91.7 mL/min in those with severe renal impairment.[2] This direct dependence on renal function for elimination is the cornerstone of its nephrotoxicity risk, as impaired clearance leads to drug accumulation and potential kidney damage. This creates a dangerous positive feedback loop where renal dysfunction causes higher drug levels, which in turn can worsen renal function.

Table 2 provides a summary of the key pharmacokinetic parameters for adefovir.

Table 2: Summary of Pharmacokinetic Parameters

Parameter	Value	Source(s)
Oral Bioavailability	59%	2
Time to Peak (Tmax​)	0.58 – 4.0 hours	2
Peak Concentration (Cmax​)	18.4 ± 6.26 ng/mL (10 mg dose)	2
Plasma Protein Binding	< 4%	3
Volume of Distribution (Vd​)	0.35 – 0.39 L/kg	14
Metabolism	Prodrug hydrolysis to adefovir; not a CYP450 substrate	2
Elimination Half-Life (t1/2​)	~7.5 hours	3
Primary Excretion Route	Renal (glomerular filtration and active tubular secretion)	3

Clinical Efficacy and Therapeutic Use

The clinical application of adefovir dipivoxil is defined by its approved indications, evidence from clinical trials, and its performance relative to other available therapies for chronic hepatitis B. Its clinical story is one of a drug that provided a significant but temporary advantage before being surpassed by more potent successors.

Approved Indications

Adefovir dipivoxil is indicated for the treatment of chronic hepatitis B (CHB) virus infection in adult and pediatric patients aged 12 years and older.[12] The initiation of therapy is recommended for patients who meet specific criteria:

• Evidence of active HBV replication (e.g., detectable HBV DNA).
• Evidence of ongoing liver inflammation, demonstrated by either:
• Persistently elevated serum aminotransferases (ALT or AST).
• Histologically active disease confirmed by liver biopsy.[2]

The approval was based on data demonstrating histological, virological, biochemical, and serological responses in a broad range of patients, including both hepatitis B e-antigen (HBeAg)-positive and HBeAg-negative individuals with compensated liver function.[3] Critically, its indication also extends to patients with clinical evidence of lamivudine-resistant HBV, a key niche that defined its early clinical utility.[12]

Dosage and Administration

• Standard Dosage: The recommended dose is a single 10 mg tablet taken orally once daily, with or without food.[4] The optimal duration of treatment has not been established and is often long-term.
• Pediatric Use: The 10 mg daily dose is also approved for adolescents aged 12 and older. The drug is not recommended for children younger than 12 years of age.[16]
• Dose Adjustment in Renal Impairment: Due to its renal excretion and potential for nephrotoxicity, dose adjustment is mandatory for patients with renal dysfunction. Failure to adjust the dose can lead to drug accumulation and increased risk of adverse events. Table 3 outlines the FDA-recommended dosing adjustments based on creatinine clearance (CrCl).[16]

Table 3: Dosage Adjustments in Renal Impairment

Creatinine Clearance (CrCl) (mL/min)	Recommended Dose and Interval	Source(s)
≥ 50	10 mg every 24 hours	16
30 to 49	10 mg every 48 hours	16
10 to 29	10 mg every 72 hours	16
Hemodialysis Patients	10 mg every 7 days (following dialysis)	16

Clinical Evidence and Comparative Efficacy

The clinical value of adefovir dipivoxil is best understood in the context of the therapies that preceded and succeeded it.

• Advantage over Lamivudine: Adefovir's primary benefit over lamivudine, the first nucleoside analog approved for HBV, was its significantly higher barrier to resistance. While resistance to lamivudine can develop rapidly, the mutations conferring resistance to adefovir emerge much more slowly, making it a more durable therapy and an effective option for patients who had failed lamivudine treatment.[3]
• Comparison with Tenofovir (TDF): Tenofovir disoproxil fumarate, another nucleotide analog developed by Gilead, has demonstrated clear superiority over adefovir in clinical trials.
• A meta-analysis of six studies involving 910 patients found that at 48 weeks, TDF was significantly more effective than adefovir at suppressing HBV DNA (Relative Risk = 2.59).[21]
• A pivotal head-to-head study showed that 76% of TDF-treated patients achieved undetectable HBV DNA (<400 copies/mL) compared to a much lower percentage for adefovir.[15]
• While the meta-analysis did not find a statistically significant difference in ALT normalization or HBeAg seroconversion, the trends consistently favored TDF.[21]
• Comparison with Entecavir (ETV): Entecavir, a potent nucleoside analog, has also proven to be more effective than adefovir.
• A meta-analysis of 13 randomized controlled trials (RCTs) with 1,230 patients concluded that ETV is superior to adefovir in achieving both virologic and biochemical responses.[22]
• At 48 weeks, 78.3% of patients on ETV achieved undetectable HBV DNA, compared to only 50.4% of patients on adefovir. The difference was highly significant.[22]
• ETV also led to significantly higher rates of ALT normalization (86.2% vs. 78.0%) and HBeAg clearance at 48 weeks.[22]
• The safety profiles of the two drugs were found to be comparable in these studies.[22]

This body of evidence positions adefovir as a "transitional" therapy. It was a crucial improvement over lamivudine but was quickly rendered a second- or third-line option by the arrival of TDF and ETV. These newer agents offer greater antiviral potency without an increased safety burden, making them the preferred first-line oral therapies in all major international treatment guidelines. The clear quantitative differences in efficacy are summarized in Table 6.

Table 6: Comparative Efficacy of Adefovir vs. Tenofovir and Entecavir (48-Week Endpoints)

Endpoint	Adefovir Dipivoxil	Tenofovir Disoproxil	Entecavir	Key Finding/Statistic	Source(s)
HBV DNA Suppression (<400 copies/mL)	~13-50%	~76%	~78%	TDF and ETV are significantly more potent than adefovir.	15
ALT Normalization	~63-78%	~69-72%	~86%	ETV is superior to adefovir; TDF shows a trend toward superiority.	15
HBeAg Seroconversion	~12-14%	~19%	~20%	No statistically significant difference, but trends favor TDF and ETV.	3

Safety Profile and Risk Management

The clinical use of adefovir dipivoxil is governed by a distinct safety profile characterized by several significant risks, most notably nephrotoxicity. These risks are highlighted in FDA-mandated boxed warnings and necessitate careful patient monitoring and management.

Boxed Warnings

The prescribing information for Hepsera® includes the following boxed warnings, which represent the most serious potential adverse reactions [16]:

1. Severe Acute Exacerbations of Hepatitis: Discontinuation of anti-HBV therapy, including adefovir, can lead to a severe rebound of hepatitis. In clinical trials, up to 25% of patients experienced ALT elevations greater than 10 times the upper limit of normal after stopping the drug. This phenomenon is believed to result from the rapid resumption of viral replication upon drug withdrawal, triggering a strong immune response against infected hepatocytes. Patients who discontinue therapy must have their hepatic function monitored closely, both clinically and with laboratory tests, for at least several months. Resumption of anti-HBV therapy may be necessary.[16]
2. Nephrotoxicity: Chronic administration of adefovir dipivoxil can cause kidney damage, particularly in patients with pre-existing renal dysfunction or those receiving concomitant nephrotoxic drugs. The toxicity typically manifests as a gradual increase in serum creatinine. This risk is the central pillar of the drug's safety concerns and mandates regular monitoring of renal function and dose adjustments as required.[3]
3. HIV Resistance: Adefovir has weak activity against HIV. In patients with unrecognized or untreated HIV co-infection, treatment with adefovir monotherapy for their HBV can select for HIV mutations that confer resistance to antiretroviral drugs. Therefore, all patients should be offered HIV antibody testing before initiating adefovir therapy.[14]
4. Lactic Acidosis and Severe Hepatomegaly with Steatosis: This is a rare but potentially fatal class-effect toxicity associated with nucleoside and nucleotide analogs. It is thought to be caused by mitochondrial dysfunction. Treatment should be suspended if clinical or laboratory findings suggest lactic acidosis or pronounced hepatotoxicity.[14]

Adverse Reactions

The adverse reactions associated with adefovir dipivoxil are summarized in Table 4. The safety profile is dominated by a single pathophysiological cascade originating from renal toxicity. The primary nephrotoxic effect on the proximal renal tubules can lead to Fanconi syndrome, a condition characterized by the urinary wasting of essential substances like phosphate, glucose, and amino acids. The resulting hypophosphatemia can, in turn, impair bone mineralization, leading to osteomalacia, which manifests as bone pain and an increased risk of fractures. This demonstrates a clear causal chain: Adefovir → Proximal Renal Tubulopathy → Fanconi Syndrome → Hypophosphatemia → Osteomalacia.[16]

Table 4: Summary of Major Adverse Reactions and Boxed Warnings

Warning/Adverse Reaction	Clinical Manifestation/Description	Management/Monitoring Recommendation	Source(s)
Severe Acute Hepatitis Exacerbation	Post-treatment rebound of hepatitis with significant ALT flares.	Monitor hepatic function closely for several months after discontinuing therapy.	16
Nephrotoxicity	Increased serum creatinine, hypophosphatemia, renal failure, Fanconi syndrome, proximal renal tubulopathy.	Monitor renal function (creatinine, phosphorus) regularly. Dose adjustment is mandatory in renal impairment.	3
HIV Resistance	Emergence of resistant HIV strains in untreated co-infected patients.	Perform HIV antibody testing prior to initiating therapy.	16
Lactic Acidosis / Severe Hepatomegaly	Rare but fatal class effect due to mitochondrial toxicity.	Suspend treatment if suspected. Monitor for symptoms like muscle pain, fatigue, dyspnea.	14
Common Adverse Reactions	Asthenia (weakness), headache, abdominal pain, nausea, diarrhea, dyspepsia, flatulence.	Symptomatic management.	14
Musculoskeletal Effects	Myopathy, osteomalacia (bone pain, fractures).	Often secondary to renal tubulopathy. Monitor for muscle or bone pain, especially in patients with renal issues.	16

Contraindications

The use of adefovir dipivoxil is contraindicated in the following situations:

• Patients with a known history of hypersensitivity to adefovir dipivoxil or any of its components.[12]
• Concurrent use with tenofovir disoproxil fumarate (Viread®) or any tenofovir-containing combination products (e.g., Atripla®, Truvada®, Stribild®). This is due to the lack of additional benefit and the potential for additive renal toxicity, as both are structurally similar nucleotide analogs eliminated via the same renal pathway.[20]

Drug-Drug Interactions

The drug interaction profile of adefovir dipivoxil is remarkably one-dimensional, revolving almost entirely around the kidney. Its lack of involvement with the CYP450 enzyme system means that a vast number of common metabolic interactions are avoided.[2] However, this places an intense focus on interactions that affect renal function. There are over 100 documented interactions, the majority of which are classified as major or moderate in severity.[26]

Mechanism-Based Interactions

Interactions can be categorized based on their underlying mechanism, as detailed in Table 5.

1. Additive Nephrotoxicity: The most significant risk arises from the co-administration of adefovir with other drugs known to be nephrotoxic. The concurrent use can potentiate the risk of kidney damage. Clinicians must carefully review a patient's entire medication list for such agents.
2. Competition for Active Tubular Secretion: Adefovir is actively secreted by renal tubules. Drugs that compete for the same transport systems (e.g., organic anion transporters, OATs) can lead to increased plasma concentrations of adefovir and/or the co-administered drug, thereby increasing the risk of toxicity.
3. Contraindicated Combination with Tenofovir: The formal contraindication with tenofovir is a reflection of its clinical obsolescence. Tenofovir is a more potent successor with a similar mechanism and toxicity profile. There is no therapeutic rationale for their combined use, which would only increase the risk of nephrotoxicity.[24]

Table 5: Clinically Significant Drug-Drug Interactions

Interacting Drug/Class	Severity	Mechanism/Potential Effect	Management Recommendation	Source(s)
Tenofovir-containing products (e.g., Viread®, Atripla®)	Major (Contraindicated)	Additive nephrotoxicity, no additional benefit.	Co-administration is contraindicated.	20
Nephrotoxic Agents (e.g., NSAIDs, aminoglycosides, cyclosporine, tacrolimus, vancomycin)	Major	Additive risk of kidney damage.	Avoid combination if possible. If necessary, monitor renal function very closely.	2
Drugs competing for tubular secretion (e.g., cidofovir, emtricitabine)	Moderate to Major	Increased serum concentrations of adefovir and/or the co-administered drug.	Monitor for adverse events associated with both drugs. Dose adjustments may be needed.	24
Pretomanid	Moderate	Pretomanid inhibits OAT3, potentially increasing adefovir concentrations.	Monitor for increased adefovir-related adverse effects.	24
Acetaminophen	Minor	Adefovir may decrease the excretion of acetaminophen, potentially increasing its levels.	Generally low clinical significance; monitor if high doses are used.	2

Regulatory and Development History

The trajectory of adefovir dipivoxil from invention to its current regulatory status is a compelling narrative of scientific discovery, strategic repurposing, clinical success, and eventual market-driven obsolescence.

Invention and Failed HIV Development

Adefovir was invented by the distinguished Czech scientist Dr. Antonín Holý at the Institute of Organic Chemistry and Biochemistry in Prague, a hub responsible for several key antiviral compounds.[3] The drug was licensed and developed by Gilead Sciences, initially as a treatment for Human Immunodeficiency Virus (HIV) infection, under the proposed brand name

Preveon.[3]

However, the development for HIV was halted. The doses required for effective anti-HIV activity, typically 60 mg or 120 mg daily, were associated with an unacceptably high frequency and severity of kidney toxicity. In a pivotal decision in November 1999, an expert advisory panel to the U.S. Food and Drug Administration (FDA) recommended against approving the drug for HIV due to these safety concerns. The FDA followed this advice, and Gilead officially discontinued its development for HIV in December 1999.[3] This failure was not due to a flawed mechanism but rather an inability to establish a safe therapeutic window for that specific indication.

Repurposing and Approval for Hepatitis B

Instead of abandoning the compound, Gilead strategically repurposed it for the treatment of chronic hepatitis B. Preclinical and early clinical data indicated that a much lower dose of 10 mg daily was effective against HBV and had a more manageable safety profile.[5]

This new development path proved successful:

• Gilead submitted a New Drug Application (NDA) to the FDA on March 21, 2002.[30]
• On August 6, 2002, the FDA's Antiviral Drugs Advisory Committee unanimously voted to recommend approval.[30]
• The U.S. FDA granted full approval for adefovir dipivoxil (brand name Hepsera®) on September 20, 2002.[3]

International Regulatory Status and Withdrawal

Following its success in the U.S., adefovir dipivoxil gained approval in other major markets.

• Gilead submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in 2002.[32]
• The EMA granted marketing authorization on March 6, 2003.[3]

The final chapter in adefovir's story in developed markets was written two decades later. As more potent and safer alternatives—notably tenofovir, also from Gilead—became the standard of care, the clinical use and commercial viability of Hepsera® declined. On December 31, 2022, the marketing authorization for Hepsera® was formally withdrawn in the European Union at Gilead's request. The reason cited was purely "commercial reasons," not new safety concerns.[33] This event marks the natural conclusion of a drug's lifecycle in a competitive therapeutic landscape, where it was ultimately displaced by its own superior successors.

Conclusion and Expert Synthesis

Adefovir dipivoxil occupies a well-defined and historically significant, yet now largely superseded, position in the therapeutic armamentarium against chronic hepatitis B. Its clinical journey is a powerful illustration of the interplay between molecular design, dose-dependent toxicity, strategic drug development, and the dynamic evolution of clinical standards of care.

The central narrative of adefovir is one of a delicate balance between efficacy and safety, a balance that was ultimately tipped by its dose-limiting nephrotoxicity. Its failure as an HIV therapy and subsequent success as an HBV therapy were not contradictory outcomes but rather two sides of the same coin, entirely dependent on the dose required to achieve a therapeutic effect. The ability of Gilead Sciences to recognize that a lower, safer dose was still effective for a different virus represents a landmark case in pharmaceutical repurposing.

Upon its approval, Hepsera® was a crucial therapeutic tool. It offered a vital solution to the growing clinical challenge of lamivudine resistance, providing a more durable treatment option with a higher genetic barrier to the development of resistance. For a time, it was an indispensable second-line agent and a cornerstone of managing difficult-to-treat HBV cases.

However, the era of adefovir's prominence was brief. The advent of more potent nucleotide and nucleoside analogs, namely tenofovir disoproxil fumarate and entecavir, marked a paradigm shift. The evidence from head-to-head clinical trials and subsequent meta-analyses was unequivocal: these newer agents offered superior virologic suppression with a comparable or, in the case of long-term renal and bone health with newer tenofovir formulations, improved safety profile. This evidence-based superiority rapidly led to the relegation of adefovir to a third-line or alternative agent in major international treatment guidelines.

Today, adefovir dipivoxil is a legacy drug in most well-resourced healthcare systems. Its commercial withdrawal from the European market underscores its obsolescence in environments where superior alternatives are readily available. Its story serves as a testament to the relentless pace of innovation in antiviral therapy. While it may still have a limited role in certain resource-constrained settings as a generic option, its primary value is now historical. It was a critical and necessary stepping stone, bridging the gap between first-generation antivirals and the highly potent, high-resistance-barrier agents that form the current standard of care for chronic hepatitis B.

Works cited

1. Adefovir dipivoxil | C20H32N5O8P - ChemSpider, accessed August 5, 2025, https://www.chemspider.com/Chemical-Structure.54855.html
2. Adefovir dipivoxil: Uses, Interactions, Mechanism of Action ..., accessed August 5, 2025, https://go.drugbank.com/drugs/DB00718
3. en.wikipedia.org, accessed August 5, 2025, https://en.wikipedia.org/wiki/Adefovir
4. Hepsera (Adefovir Dipivoxil): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 5, 2025, https://www.rxlist.com/hepsera-drug.htm
5. Adefovir - Bionity, accessed August 5, 2025, https://www.bionity.com/en/encyclopedia/Adefovir.html
6. Adefovir dipivoxil (GS 0840, CAS Number: 142340-99-6) | Cayman ..., accessed August 5, 2025, https://www.caymanchem.com/product/28373/adefovir-dipivoxil
7. Definition of adefovir dipivoxil - NCI Drug Dictionary, accessed August 5, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/adefovir-dipivoxil
8. Adefovir dipivoxil - Bio-X ™ | 142340-99-6 | BA164139 - Biosynth, accessed August 5, 2025, https://www.biosynth.com/p/BA164139/142340-99-6-adefovir-dipivoxil-bio-x
9. Adefovir dipivoxil | CAS 142340-99-6 | SCBT - Santa Cruz Biotechnology, accessed August 5, 2025, https://www.scbt.com/p/adefovir-dipivoxil-142340-99-6
10. Adefovir Dipivoxil | C20H32N5O8P | CID 60871 - PubChem, accessed August 5, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Adefovir-Dipivoxil
11. What is the mechanism of Adefovir Dipivoxil? - Patsnap Synapse, accessed August 5, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-adefovir-dipivoxil
12. Adefovir Dipivoxil: Package Insert / Prescribing Information - Drugs.com, accessed August 5, 2025, https://www.drugs.com/pro/adefovir-dipivoxil.html
13. Adefovir - LiverTox - NCBI Bookshelf, accessed August 5, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548633/
14. Adefovir | Davis's Drug Guide for Rehabilitation Professionals, accessed August 5, 2025, https://fadavispt.mhmedical.com/content.aspx?bookid=1873§ionid=139000487
15. A Randomized, Double-Blind, Comparison of Tenofovir DF (TDF) versus Adefovir Dipivoxil (ADV) for the Treatment of HBeAg Positive Chronic Hepatitis B (CHB): Study GS-US-174-0103 - NATAP, accessed August 5, 2025, https://www.natap.org/2007/AASLD/AASLD_34.htm
16. HEPSERA® (adefovir dipivoxil) Tablets, for oral use, accessed August 5, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021449s024lbl.pdf
17. Understanding adefovir pharmacokinetics as a component of a transporter phenotyping cocktail - PubMed, accessed August 5, 2025, https://pubmed.ncbi.nlm.nih.gov/38546841
18. go.drugbank.com, accessed August 5, 2025, https://go.drugbank.com/drugs/DB00718#:~:text=Following%20oral%20administration%2C%20adefovir%20dipivoxil,of%20the%20cytochrome%20P450%20enzymes.
19. Adefovir (oral route) - Side effects & dosage - Mayo Clinic, accessed August 5, 2025, https://www.mayoclinic.org/drugs-supplements/adefovir-oral-route/description/drg-20061469
20. Adefovir Uses, Side Effects & Warnings - Drugs.com, accessed August 5, 2025, https://www.drugs.com/mtm/adefovir.html
21. Comparison of the efficacy of tenofovir and adefovir in the treatment ..., accessed August 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3063232/
22. Comparison of entecavir and adefovir for the treatment of chronic ..., accessed August 5, 2025, https://bjid.org.br/en-comparison-entecavir-adefovir-for-treatment-articulo-S1413867012000657
23. What are the side effects of Adefovir Dipivoxil? - Patsnap Synapse, accessed August 5, 2025, https://synapse.patsnap.com/article/what-are-the-side-effects-of-adefovir-dipivoxil
24. Adefovir: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 5, 2025, https://www.rxlist.com/adefovir/generic-drug.htm
25. Adefovir Dipivoxil Tablets - accessdata.fda.gov, accessed August 5, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202051Orig1s000lbl.pdf
26. Adefovir Interactions Checker - Drugs.com, accessed August 5, 2025, https://www.drugs.com/drug-interactions/adefovir.html
27. Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) - HIV Drug Interactions, accessed August 5, 2025, https://www.hiv-druginteractions.org/interactions/96944
28. ADEFOVIR DIPIVOXIL - ORAL (Hepsera) side effects, medical uses, and drug interactions., accessed August 5, 2025, https://www.medicinenet.com/adefovir_dipivoxil-oral/article.htm
29. adefovir dipivoxil, Hepsera (adefovir) dosing, indications ..., accessed August 5, 2025, https://reference.medscape.com/drug/adefovir-dipivoxil-hepsera-342635
30. FDA Advisory Committee Unanimously Supports Approval of Gilead's Adefovir Dipivoxil to Treat Chronic Hepatitis B, accessed August 5, 2025, https://www.gilead.com/news/news-details/2002/fda-advisory-committee-unanimously-supports-approval-of-gileads-adefovir-dipivoxil-to-treat-chronic-hepatitis-b
31. Drug Approval Package: Hepsera (Adefovir Dipivoxil) NDA #21-449 - accessdata.fda.gov, accessed August 5, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-449_Hepsera.cfm
32. Gilead Submits Marketing Authorisation Application for Adefovir Dipivoxil 10 mg for Treatment of Chronic Hepatitis B; EU Application Follows Submission to FDA, accessed August 5, 2025, https://www.gilead.com/news/news-details/2002/gilead-submits-marketing-authorisation-application-for-adefovir-dipivoxil-10-mg-for-treatment-of-chronic-hepatitis-b-eu-application-follows-submission-to-fda
33. Hepsera | European Medicines Agency (EMA), accessed August 5, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/hepsera
34. Hepsera (adefovir dipivoxil) | EMA - European Union, accessed August 5, 2025, https://www.ema.europa.eu/en/documents/public-statement/public-statement-hepsera-adefovir-dipivoxil-withdrawal-marketing-authorisation-european-union_en.pdf